Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00587691

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (DES)

An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Sponsor: Opexa Therapeutics, Inc.

Conditions Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive

Interventions Tovaxin Autologous T Cell Vaccine

Updated 6 times since 2017 Last updated: Jan 9, 2017 Started: Jul 31, 2002 Primary completion: Jun 30, 2007 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis, Secondary Progressive and is currently completed. Opexa Therapeutics, Inc. leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Opexa Therapeutics, Inc.

Data source: Opexa Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bellaire, United States
• Houston, United States